(PDF) P3.01-03 the Cost Benefit From Second Line

P3.01-03 the Cost Benefit From Second Line Immunotherapy in Metastatic NSCLC: ASCO Value Framework Prospective

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2018.08.1563

Full Text

Abstract

Available in full text

Categories

Respiratory Medicine

Date

October 1, 2018

Authors

Publisher

Elsevier BV

Related search

High TMB Predicts Immunotherapy Benefit in NSCLC

Cancer Discovery

English

P3.01-110 Defining Aggressive Disease in Patients With Advanced NSCLC Receiving Second-Line Treatment: A Systematic Review

Journal of Thoracic Oncology

Respiratory Medicine

English

P3.01-86 Treatment Outcomes With Reduced Frequency of Nivolumab Dosing as Second-Line Therapy in Patients With Advanced NSCLC

Journal of Thoracic Oncology

Respiratory Medicine

English

Cost-Effectiveness Analysis of Biomarker-Guided Treatment for Metastatic Gastric Cancer in the Second-Line Setting

Journal of Oncology

English

P2.15-18 Cost-Effectiveness Analysis of Second-Line Immune Checkpoint Inhibitors for Advanced NSCLC in Colombia

Journal of Thoracic Oncology

Respiratory Medicine

English

PCN37 Cost-Minimization Analysis of Second-Line Chemotherapy for Non-Small-Cell Lung Cancer (NSCLC)

Value in Health

Occupational Health

English

P3.01-65 First-Line Radical Local Therapy May Provide Additional Survival Gain for Patients With EGFR-Mutant Metastatic NSCLC Receiving TKIs

Journal of Thoracic Oncology

Respiratory Medicine

English

P3.01-13 Prognosis of Non-Driver, Never Smoker Metastatic Non-Small Lung Cancer (NSCLC)

Journal of Thoracic Oncology

Respiratory Medicine

English

P2.01-34 Prognostic Value of Neutrophil to Lymphocyte Ratio for Metastatic NSCLC Patients Treated With Immunotherapy and Ramucirumab Plus Docetaxel.

Journal of Thoracic Oncology

Respiratory Medicine

English